ARTICLE | Company News
Takeda adds oncolytic viruses to pipeline via Turnstone deal
December 19, 2019 10:19 PM UTC
Updated on Dec 20, 2019 at 4:10 AM UTC
Takeda has partnered with Turnstone to discover and develop immunotherapies using the biotech’s engineered vaccinia virus platform in a deal that gives the Japanese pharma its first oncolytic virus.
Turnstone Biologics Inc. will receive upfront and near-term milestone payments and an equity investment totaling $120 million. President and CEO Sammy Farah said the investment will be part of a financing round...